Fully funded by 
Content independently selected
Incremental diagnostic yield dropped substantially after age 70-75 years.
2-sample tests were thought to offer greater sensitivity with intermittent bleeding.
Immune checkpoint inhibitors show efficacy in a small number of patients.
Surgeons, medical oncologists and gastrointestinal oncologists reviewed current evidence.
An analysis of data from the Hospital Episode Statistics over a 10-year period
Reflects new data for liver, pancreatic, soft tissue, and gastric cancer.
Meta-analysis of outcomes with conservatively managed low- and high-risk lesions.
Update incorporates more options for BRAF-mutated tumors.
A combination of aggressive chemotherapy, radiation, and a BP drug.
Data also show improved recurrence-free survival.
OSLO-COMET shows similar long-term efficacy, less short-term morbidity.
An on-site interview with Åsmund Avdem Fretland, MD.
An interview with Hedy L. Kindler, MD, regarding the benefit of olaparib in BRCA-positive disease.
Phase 3 data show significant benefit over symptom management alone.
Addition to gemcitabine failed to improve DFS.
Practice-changing findings from the phase 3 POLO trial.
Gastric cancer is the fifth most frequently diagnosed cancer worldwide, with a poor outcome after surgery.
